AHNAK2 and non-small cell lung carcinoma: In this validation cohort, the overall mutation frequency of AHNAK2 was 14% with melanoma (17.2%) ranking the most prevalent cancer type followed by non-small cell lung cancer (12.5%) and bladder cancer (7.4%).